Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Vorinostat Maintenance After ASCT for NHL
NCT00992446Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2010
- Primary completion
- Jun 2015
- Modality
- Modified Peptides, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, vorinostat in non-Hodgkin lymphoma (NHL), sponsored by Fred Hutchinson Cancer Center. Started Sep 2010; status: completed.
02
Drugs
bortezomibvorinostat
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00992446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00992446.